u/cryptarsh

Proposal link: https://www.researchhub.com/proposal/7659/engineering-morphogen-gradients-to-grow-larger-spatially-patterned-human-cortical-organoids

Genuine question for the academic crowd here.

A cortical organoid methods proposal from Joao Pereira's lab at UAB just closed funding on ResearchHub at $25K, with submission to fully funded running roughly two and a half months. Five named backers (one institutional, four community). The full proposal is public from day one with line-item budget, Gantt chart, methods, statistical plan, controls, exclusion criteria, if-then contingencies, four named peer reviews, and a DOI assigned at funding.

The thing I'd like the academic perspective on is how this kind of mechanism actually compares to NIH R03 / R21 for early-stage methods work. R21s are 9 to 12 months from submission to award when funded. R03s are similar. For a $25K methods proof-of-concept, the slower mechanism eats most of the actual experiment's timeline.

My specific questions:

1. For PIs reading this: would you actually use this mechanism for a small methods pilot, or does the lack of NIH-style indirect-cost recovery kill it for institutional reasons?
2. For program officers or anyone who's served on study sections: is preregistration plus open peer review on a public platform meaningfully different from an R21 review, or is it the same review with worse incentives?
3. What's the strongest counterargument you'd make against this kind of funding for early methods work?

The proposal itself is preregistered with named acceptance criteria, full code release on GitHub, data to GEO, preprint to bioRxiv at the time of journal submission. KOLF2.1J line, n=3 Answer ALS validation lines. Part of an open RFP pool (Project Gigabrain Track 1) with six other proposals in flight.

Curious about both supportive and critical takes. The mechanism is new enough that the field hasn't really worked out whether it's a useful adjunct or a niche path that only works for specific kinds of pre-PI work.

The peptide therapeutics conversation has spent years on a small set of targets: AMPK (the cell's energy switch), mitochondrial peptides like MOTS-c and humanin, the gut-brain axis, and BDNF (a growth factor that protects neurons). Metformin hits all four. It gets into the brain. It triggers natural GLP-1 release from the gut (the same hormone Ozempic and Wegovy mimic). It calms brain inflammation. In animals, it grows new neurons in the hippocampus. In two large human studies, long-term users had slower memory decline and lower dementia rates.

What the field does not have is a clean look at the brain on actual scans. No one has measured how well metformin users' brains clear waste, how much inflammation is sitting in the wiring, or how healthy the wiring is, compared to matched non-users at scale.

Dr. Faye McKenna's lab at Albert Einstein / Montefiore is about to. They're using UK Biobank, the world's largest brain scanning study (around 100,000 brain MRIs plus full prescription records and 325 markers in blood). They'll match people on metformin to similar people who aren't, on age, sex, weight, blood sugar, blood pressure, smoking, activity, neighborhood, and the main genetic risk factor for Alzheimer's. They'll measure three things on the brain scans (waste clearance, inflammation in the wiring, wiring health), the same comparison for body fat (liver, belly, muscle), and then test whether body changes lead to brain changes lead to better thinking and memory.

Plan is locked in writing before the data is opened. Code, results, and a preprint will all be public.

If the brain results hold, metformin becomes the first drug on this pathway with real human imaging evidence linking body fat changes to brain waste clearance to memory and thinking. If they don't, that's a publishable answer too, and it tells the rest of the longevity drug field something important.

You know how some people on here report amazing results and others barely see a difference on the same dose? I found a research proposal that might explain why.

The study is looking at whether your gut microbiome, specifically the short-chain fatty acids (SCFAs) your gut bacteria produce, acts as a modifier for how GLP-1 receptor agonists work in your body. Basically, different gut bacteria might mean different people get different effects from the same drug.

It's focused on the South Asian metabolic phenotype specifically, since that population has really high rates of metabolic syndrome and tends to respond differently to these kinds of treatments.

If this research pans out, it could eventually mean doctors test your gut microbiome before prescribing to predict how well you'll respond. Or even that adjusting your microbiome (through diet, probiotics, whatever) could improve how well the drug works.

The photon energy at 60 Hz is roughly 2.5 × 10⁻¹³ eV, about 10¹¹ times below thermal energy at body temperature. That should make any biological effect impossible.

But there's a peer-reviewed research proposal on ResearchHub asking a question I can't immediately dismiss: could chronic low-level ELF-EMF exposure (8-20 milligauss, well below ICNIRP thresholds) measurably weaken collagen and increase soft tissue injury risk?

The proposal sidesteps the photon energy problem by leaning on the radical pair mechanism, the same class of mechanism proposed for avian magnetoreception. It then traces three pathways:

1. Altered radical pair spin dynamics → increased ROS → upregulation of MMP-2 (a collagen-degrading enzyme)
2. ROS interference with prolyl hydroxylase activity → disrupted proline hydroxylation → structurally weaker collagen
3. ELF-EMF effects on mitochondrial electron transport chain → reduced cellular energy for tissue maintenance

My question: is the radical pair mechanism physically plausible at 60 Hz and 8-20 milligauss? Does the Larmor precession frequency at those field strengths fall anywhere near the relevant spin dynamics timescales, or is the coupling too weak to matter?

Here's the link for reference: https://www.researchhub.com/proposal/25383/electromagnetic-fields-and-soft-tissue-injury-susceptibility

This might be old news to some of you, but for those who missed it: earlier this year a viral post claimed the 49ers' high rate of Achilles and tendon injuries could be linked to chronic ELF-EMF exposure from an electrical substation next to their practice facility. It blew up, got 22 million views, and then mostly got dismissed by mainstream sports media.

What didn't get coverage is what happened after. ResearchHub put out a formal research call on the underlying scientific question: can chronic low-frequency EMF exposure at infrastructure levels (5-50 mG, 60 Hz) affect collagen integrity or soft tissue injury risk? Twelve research teams have submitted proposals to study it through in vitro work on tendon cells, epidemiological analysis, and biomechanical testing. All preregistered and open-access.

Given how much this community understands about electromagnetic fields and tissue interaction, I thought it was worth sharing. The proposals are publicly visible on ResearchHub if you're curious what the researchers are actually planning to study. There's also a crowdfunding component if anyone wants to back it.

https://www.researchhub.com/proposal/25383/electromagnetic-fields-and-soft-tissue-injury-susceptibility

Interested to hear what people here think about the plausibility of the mechanism.

Most WHM research has focused on healthy people. The immune modulation findings from the 2014 PNAS study are compelling, but what about people dealing with active cancer and elevated chronic inflammation? That question hasn't been rigorously studied yet.

A team led by Sara Matijevic, PhD at Oxford is running a 16-week feasibility pilot to find out. Physician-gated, preregistered, fully open-access. Wim Hof himself is a special advisor on the study.

I'm sharing this because I work with ResearchHub Foundation, which is hosting the proposal, and this community felt like the right place to bring it. The study is peer-reviewed and open for community crowdfunding.

Checkout the full proposal here: https://www.researchhub.com/proposal/4459/researchhub-proposal-wim-hof-method-whm-cold-exposure-for-cancer-instructor-guided-citizen-pilot